Kidney involvement in Fabry disease: Results of enzyme replacement therapy;Atteinte rénale de la maladie de Fabry: Résultats de l'enzymothérapie

Medecine/Sciences

Volumn 21, Issue SPEC. ISS. NOV., 2005, Pages 23-25

  Grünfeld, Jean Pierre ^a   Noël, Laure Hélène ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE;

CONFERENCE PAPER; ENDOTHELIUM CELL; ENZYME REPLACEMENT; ENZYME THERAPY; FABRY DISEASE; HEMIZYGOSITY; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; PILOT STUDY; RISK BENEFIT ANALYSIS; SUBSTITUTION THERAPY;

EID: 29944434714     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20052111s23     Document Type: Conference Paper

References (11)

1. Thadhoni R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61: 249-55.
2. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-38.
3. Gubler MC, Lenoir G, Grünfeld JP, et al. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 1978; 13: 223-35.
4. Grünfeld JP, Le Porrier M, Droz D, et al. La transplantation rénale chez les sujets atteints de maladie de Fabry. Nouv Presse Med 1975; 29: 2081-5.
5. Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000; 69: 2337-9.
6. t. Thurberg BL, Rennke H, Robert B, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-46.
7. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safty and efficacy on enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65-74.
8. De Schoenmakere G, Chauveau D, Grünfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003; 18: 33-5.
9. Kosch M, Koch HG, Oliveira JP, et al. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int 2004; 66: 1279-82.
10. Mignani R, Panichi V, Giudicissi A, et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int 2004; 65: 1381-5.
11. Brenner BM, Grünfeld JP. Renoprotection by enzyme replacement therapy. Curr Opin Nephrol Hypertens 2004; 13: 231-41.